Abstract: FR-PO766
Long Term Effects of Expanded Hemodialysis (HDx) on Clinical and Laboratory Parameters in a Large Cohort of Dialysis Patients
Session Information
- Dialysis: Inflammation and Infection
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Bunch, Alfonso, RTS, Bogota, Colombia
- Nilsson, Lars-Goran, Baxter International Inc., Lund, Sweden
- Vesga, Jasmin, RTS, Bogota, Colombia
- Ardila, Freddy, RTS, Bogota, Colombia
- Zuniga, Eduardo, RTS, Bogota, Colombia
- Alarcon, Juan, RTS, Bogota, Colombia
- Suarez, Adriana Marcela, RTS, Bogota, Colombia
- Sanchez, Ricardo, Universidad Nacional de Colombia, Bogotá, Colombia
- Sanabria, Mauricio, RTS Baxter, Bogota, Colombia
Background
Expanded hemodialysis (HDx) enabled by medium cut off membrane provides clearance of large middle molecules which have been linked to inflammation, immune modulation and atherosclerosis. The long term effects of HDx on serum levels of small solutes and albumin has not been investigated in large cohort of patients.
Methods
Multicenter prospective study in prevalent hemodialysis patients, older than 18 years old; enrolled from September 1 to November 30 of 2017, and converted to HDx using Theranova 400 (3 sessions per week, 4 hours per session, same heparin dose) . Albumin assay used was bromocresol blue with laboratory reference values between 3,5 gr/dl – 5,1 gr/dl
Measurements were done at baseline, week 2, and month 1,2,3,4,5,6; descriptive statistics and ANOVA were used.
Results
We analyzed data on 524 patients, 61.6% ( n=323) men, mean age 60.1 years (SD=15.3), dialysis vintage was 5.4 years ( SD=5.01).
We did not observe clinically significant differences in laboratory variables after 6 months of intervention with expanded hemodialysis; details are presented in Table 1.
We found an initial small decrease in serum albumin level which stabilized and within the normal range per our laboratory references. See Table 1
Dialysis performans adequacy (Kt/V) was achieved. No clinically significant differences in laboratory values at 6 months with HDx was observed (Table 2).
Conclusion
The expended hemodialysis (HDx) shows a very good safety and performance profile during the first three months of use.
Funding
- Commercial Support –